A Study of HSP990 Administered by Mouth in Adult Patients With Advanced Solid Tumors

Phase 1

Completed

• Conditions: Advanced Solid Malignancies
• Interventions: Drug: HSP990

• Registration Number: NCT00879905
• Lead Sponsor: Novartis Pharmaceuticals

Brief Summary

This study will study the safety, tolerability and metabolism of a drug called HSP990 when given by mouth once a week or twice weekly to subjects with advanced solid tumors.

Detailed Description

Not available

Study Timeline

• Study First Submitted: 2009-04-09
• Study First Submitted QC: 2009-04-10
• Study First Posted: 2009-04-13
• Study Start: 2009-05
• Primary Completion: 2012-07
• Study Completion: 2012-07
• Status Verified: 2012-10
• Last Update Submitted: 2020-12-06
• Last Update Posted: 2020-12-08

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 64

Inclusion Criteria

1. Patients with histologically confirmed, advanced malignant solid tumors whose disease has progressed on standard therapy or for whom no standard therapy exists
2. All patients must have at least one measurable lesion as defined by RECIST. Irradiated lesions are only evaluable for disease progression
3. All patients must have documented progressive disease before entering the study
4. Age ≥ 18 years
5. World Health Organization (WHO) Performance Status ≤ 2
6. Life expectancy of ≥ 12 weeks
7. Patients must have the certain laboratory values
8. Patients able and willing to swallow capsules
9. Ability to understand the patient information and informed consent form and comply with the protocol
10. Signed and dated written informed consent is available
11. Only for patients enrolled at MTD: willing to provide a fresh pre-dose and post-dose tumor biopsy.

Exclusion Criteria

1. Patients with present or history of CNS metastasis.

2. Prior treatment with any Hsp90 or HDAC inhibitor compound.

3. Patients who have not recovered from side effects of previous systemic anticancer therapy to < CTCAE Grade 2 prior to the first dose

4. Patients identified to be "poor or intermediate CYP2C9 metabolizers"

5. Patients who received systemic anti-cancer treatment prior to the first dose of HSP990 within the following time frames:

   • Patients who have received cyclical chemotherapy within a period of time that is shorter than the cycle length used for that treatment (e.g., 6 weeks for nitrosourea, mitomycin-C) prior to starting study drug or who have not recovered from the side effects of such therapy
   • Patients who have received biologic therapy (e.g., antibodies) within a period of time that is ≤ 4 weeks prior to starting study drug or who have not recovered from the side effects of such therapy
   • Patients who have been treated with a continuous or intermittent small molecule therapeutic within a period of time that is ≤ 5 t1/2 or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy
   • Patients who have received any other investigational agents within a period of time that is ≤ 5 t1/2 or less than the cycle length used for that treatment or ≤ 4 weeks (whichever is shorter) prior to starting study drug or who have not recovered from the side effects of such therapy
   • Patients who have received wide field radiotherapy (including therapeutic radioisotopes such as strontium 89) ≤ 4 weeks or limited field radiation for palliation ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy.
   • Patients who have undergone major surgery ≤ 2 weeks prior to starting study drug or who have not recovered from side effects of such therapy

6. Treatment with therapeutic doses of sodium warfarin (Coumadin).

7. Patients using medications that are CYP2C9 inhibitors and/or medications known to have QT prolongation effect and cannot be switched or discontinued to an alternative drug prior to commencing HSP990 dosing.

8. Unresolved diarrhea ≥ CTCAE grade 2

9. Patients who do not have either an archival tumor sample available or readily obtainable in the course of the study or are unwilling to have a fresh tumor sample collected at baseline.

10. Pregnant or lactating women.

11. Fertile women of childbearing potential (WCBP) not using adequate contraception (abstinence, oral contraceptives, intrauterine device or barrier method of contraception in conjunction with spermicidal jelly or surgically sterile). Male patients whose partners are WCBP, not using adequate contraception.

12. Acute or chronic liver disease.

13. Acute or chronic renal disease.

14. Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of HSP990

15. Other concurrent severe and/or uncontrolled medical conditions (e.g., uncontrolled diabetes, active or uncontrolled infection) that could cause unacceptable safety risks or compromise compliance with the protocol.

16. Known diagnosis of HIV infection (HIV testing is not mandatory).

17. Patients with a history of another primary malignancy that is currently clinically significant or currently requires active intervention

18. Cardiac exclusion criteria:

    • History (or family history) of long QT syndrome.
    • Mean QTcF ≥ 480 msec on screening ECG
    • History of clinically manifest ischemic heart disease including myocardial infarction, or unstable angina ≤ 3 months prior to study start.
    • Left ventricular (LV) dysfunction (LVEF ≤ 45%) by MUGA or ECHO
    • Clinically significant ECG abnormalities including one or more of the following: left bundle branch block (LBBB), right bundle branch block (RBBB) with left anterior hemiblock (LAHB), or 3rd degree AV block.
    • History or presence of atrial fibrillation, atrial flutter or ventricular arrhythmias including ventricular tachycardia or Torsades de Pointes.
    • Clinically significant resting bradycardia (< 50 beats per minute).
    • Patients who are currently receiving treatment with any medication which has a relative risk or prolonging the QTcF interval or inducing Torsades de Pointes (as listed in Post-text supplement 2) and cannot be switched or discontinued to an alternative drug prior to commencing HSP990 dosing.
    • Obligate use of a cardiac pacemaker.
    • Other clinically significant heart disease (e.g., congestive heart failure, uncontrolled hypertension, history of labile hypertension, or history of poor compliance with an antihypertensive regimen)

Other protocol-defined inclusion/exclusion criteria may apply

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
once weekly dosing schedule	HSP990	-
twice weekly dosing schedule	HSP990	-

Primary Outcome Measures

Name	Time	Method
Maximum Tolerated Dose of HSP990 in patients treated once weekly or twice weekly	At the end of the dose escalation phase of the study

Secondary Outcome Measures

Name	Time	Method
Preliminary Efficacy	Every 2 months (or 8 weeks, which equals 2 treatment cycles)
True DLT rate	At the end of the 1st 4 weeks of treatment
Drug metabolism in Humans, PK, PD	every 4 weeks

Trial Locations

Locations (1)

Novartis Investigative Site; 🇪🇸 Barcelona, Cataluña, Spain